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Abstract.
Background: Identifying translatable, non-invasive biomarkers of muscular dystrophy that better reflect the disease pathology
than those currently available would aid the development of new therapies, the monitoring of disease progression and the response
to therapy.
Objective: The goal of this study was to evaluate a panel of serum protein biomarkers with the potential to specifically detect
skeletal muscle injury.
Method: Serum concentrations of skeletal troponin I (sTnI), myosin light chain 3 (Myl3), fatty acid binding protein 3 (FABP3)
and muscle-type creatine kinase (CKM) proteins were measured in 74 Duchenne muscular dystrophy (DMD), 38 Becker muscular
dystrophy (BMD) and 49 Limb-girdle muscular dystrophy type 2B (LGMD2B) patients and 32 healthy controls.
Results: All four proteins were significantly elevated in the serum of these three muscular dystrophy patient populations when
compared to healthy controls, but, interestingly, displayed different profiles depending on the type of muscular dystrophy.
Additionally, the effects of patient age, ambulatory status, cardiac function and treatment status on the serum concentrations of
the proteins were investigated. Statistical analysis revealed correlations between the serum concentrations and certain clinical
endpoints including forced vital capacity in DMD patients and the time to walk ten meters in LGMD2B patients. Serum
concentrations of these proteins were also elevated in two preclinical models of muscular dystrophy, the mdx mouse and the
golden-retriever muscular dystrophy dog.
Conclusions: These proteins, therefore, are potential muscular dystrophy biomarkers for monitoring disease progression and
therapeutic response in both preclinical and clinical studies.
Keywords: Muscular dystrophy, biomarker, skeletal troponin I, myosin light chain 3, creatine kinase, fatty acid binding
protein 3
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INTRODUCTION
The muscular dystrophies are a heterogeneous group
of genetic disorders that result in progressive skeletal
muscle weakness and wasting [1]. There are nine major
forms of muscular dystrophy that differ clinically in
many respects including age of onset, spectrum of
muscle groups affected, severity of muscle injury and
lethality [1]. Duchenne muscular dystrophy (DMD) is
one of the most severe and common forms of mus-
cular dystrophy with a prevalence of approximately
1 in 3,500–6,000 live male births [2]. DMD results
from mutations in the DMD gene that results in an
absence of dystrophin protein expression [3]. Becker
muscular dystrophy (BMD) is caused by mutations
that lead to partial dystrophin deficiency resulting in a
milder form of the disease with later onset and greater
life expectancy [3]. Limb-girdle muscular dystrophy
type 2B (LGMD2B) is an autosomal recessive disorder
resulting from mutations in the DYSF gene that lead to
dysferlin deficiency [4]. Clinically, LGMD2B results
in progressive proximal muscle weakness, diagnosed
when patients are in their 20’s and 30’s, but, unlike
DMD and BMD, typically does not affect the cardiac
and respiratory muscles [4, 5].
There are very few pharmacological treatment
options for muscular dystrophy [6]. For DMD and
BMD patients corticosteroid treatment is the only
intervention consistently shown to delay disease pro-
gression, but with potentially treatment limiting side
effects of weight gain, loss of bone density and behav-
ioral problems with long-term use [7, 8]. For LGMD2B
corticosteroid treatment has proven ineffective [5].
Fortunately, a number of therapeutics with different
modes of action are currently in late pre-clinical devel-
opment or early clinical trials offering hope that new
treatment options for muscular dystrophy will become
available [6, 9].
The progression of new therapeutics toward clinical
testing has highlighted the need for improved out-
come measures and biomarkers to support regulatory
approval [10–12]. A number of clinical assessments
are available for evaluating functional improvement in
muscular dystrophy patients including the 6 minute
walk test, timed functional tests, forced vital capac-
ity (FVC) and the North Star Ambulatory Assessment
(NSAA), among others [11]. Total serum creatine
kinase (CK) is the standard clinical chemistry test that
is used to diagnose muscular dystrophy [13]. This test
is based on measuring the enzymatic activity of CK
present in the serum after release from damaged mus-
cle tissue [13]. While this widely available test is useful
for detecting muscle injury, serum CK activity does
not correlate well with disease severity in muscular
dystrophy patients [11]. This is due to a number of con-
founding factors affecting a patient’s serum CK level
including age, the level of physical activity and the
amount of muscle mass [11, 14], as well as factors that
affect CK enzyme activity such as serum glutathione
levels and treatment with certain drugs [15].
Numerous research teams have described novel
potential biomarkers for monitoring disease progres-
sion and drug efficacy in muscular dystrophy patients,
particularly DMD, including circulating microRNA
[16–19] and proteins identified in serum and urine
[20–22]. Two recent reports utilized proteomics
approaches to comprehensively profile the proteome
of serum from DMD and BMD patients [14, 23]. Both
groups identified a number of proteins involved in mus-
cle function and metabolism that were significantly
elevated in the serum of muscular dystrophy patients
when compared to healthy controls. Promisingly, a
number of these identified muscle-derived proteins
were common to both studies and correlated with
disease severity in DMD and BMD patients. While
the experimental approaches used in these reports
were semi-quantitative it suggested that the strategy
of measuring serum concentrations of muscle-derived
proteins could provide useful biomarkers for monitor-
ing disease progression in muscular dystrophy patients.
Here we report on the results of a multiplexed elec-
trochemiluminescent enzyme-linked immunosorbent
assay (ELISA) approach to quantitatively measure the
serum concentrations of four proteins, abundant in
skeletal muscle tissue, in serum from DMD, BMD
and LGMD2B patients. The four proteins measured are
the myofibrillar proteins skeletal troponin I (sTnI) and
myosin light chain 3 (Myl3), creatine kinase muscle-
type (CKM) and the lipid transport protein fatty acid
binding protein 3 (FABP3). Using clinical assess-
ments, such as FVC, NSAA score, ambulatory status
and cardiac function, we sought to determine if mea-
suring serum concentrations of these muscle-derived
proteins better reflected the patients’ disease state than
CK activity.
MATERIALS AND METHODS
Subjects
Serum samples from 38 BMD and 49 LGMD2B
patients and 100 serum samples from 74 DMD patients
were obtained from Newcastle University and the Jain
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Foundation through the MRC Centre for Neuromus-
cular Diseases Biobank. Collection of samples from
patients and their use in research have been ethically
approved by the NRES Committee North East – New-
castle and North Tyneside 1. For the healthy controls
18 serum samples were purchased from Bioreclama-
tionIVT (Nassau, NY) and 14 serum samples were
obtained from the Pfizer Research Support Program
(Groton, CT). Collection of samples through the Pfizer
Research Support Program was ethically approved by
Pfizer’s Institutional Review Board and conducted by
the Pfizer Global Occupational Health and Wellness
Clinic.
Muscle protein immunoassay and clinical
chemistry
sTnI, FABP3, Myl3 was quantified in serum sam-
ples using the Meso Scale Discovery (MSD, Rockville,
MD) Muscle Injury Panel 1 reagent kit (catalog #
K15181C). CKM was measured using the MSD Mus-
cle Injury Panel 2 reagent kit (catalog # K15180C).
Both assays were run and measured as per the manu-
facturer’s instructions. Subject samples were diluted
to be within the dynamic range of the assay. For
sTnI, FABP3, Myl3 testing, the muscular dystrophy
patients’ samples were diluted 1:8 while control sub-
ject samples were diluted 1:4. CKM measurement for
the DMD, BMD and LGMD2B patients required sam-
ples to be diluted from 1:200 to 1:800 to be within
the dynamic range of the assay while normal control
subjects required dilution of 1:25. ALT, AST and total
serum CK were analyzed by standard clinical chem-
istry techniques on the Siemens Advia 2400 platform.
Statistical analysis
Data were transformed and tested for the normality
assumption using the Shapiro-Wilk Test. Comparisons
between groups were made using ANOVA (para-
metric) and Kruskal-Wallis (nonparametric) Tests.
Correlation analyses were performed using Spear-
man’s Correlation (order statistics). Data from a
subject with two serial samples were evaluated with
ANOVA on paired differences and repeated measures
ANOVA. All analyses were performed using SAS ver-
sion 9.2, Cary, N. Carolina. All graphs were generated
using Graphpad Prism version 6.03.
RESULTS
Validation of assay performance
Numerous recent reports have demonstrated the
potential utility of measuring the serum concentrations
of muscle-derived proteins as biomarkers of muscle
injury [14, 23, 24]. We have extensively used a mul-
tiplexed immunoassay to monitor serum and plasma
concentrations of the muscle-derived proteins sTnI,
Myl3, FABP3 and CKM in preclinical muscle dis-
ease and muscle injury studies in rodents. While these
assays were developed and validated using rat mus-
cle proteins and homogenates, the highly conserved
amino acid sequence of the target proteins between
all species, including human, suggested these assay
could be applied to other species without modifi-
cation (Table S1). To validate the assays for use
with human serum samples, purified recombinant full-
length FLAG-tagged human sTnI, CKM, Myl3 and
FABP3 were tested. SDS-PAGE analysis followed by
silver staining (Figure S1A) and Western blot analysis
(Figure S1B) to detect the FLAG tag confirmed both
the purity and expected molecular weights of the tar-
get proteins. These proteins were subsequently tested
in the muscle protein immunoassays as part of the assay
validation.
Dilution linearity of the recombinant human pro-
teins was observed between the concentrations of 160
and 5 ng/ml with FABP3, 320 and 5 ng/ml with Myl3,
250 and 2 ng/ml with sTnI and 200 and 6 ng/ml with
CKM (Figure S1C). No cross-reactivity of the assays
with the other purified proteins tested was observed
Table 1
Characteristics of muscular dystrophy patients and healthy controls
Control (n = 32) BMD (n = 38) DMD (n = 74) LGMD2B (n = 49)
Age (years) 21.1 ± 15.2 29.6 ± 20.4 12.6 ± 5.8 37.3 ± 10.5
Age range (years) 5–53 4–85 3–25 18–66
Sex - Male 32 (100%) 38 (100%) 74 (100%) 20 (41%)
Non-ambulant 9 (24%) 29 (39%) 16 (33%)
Treated with corticosteroids 62 (84%)
Treated for cardiomyopathy 28 (38%)
Follow-up sample available 26 (35%)
Data are mean ± standard deviation, age range or number of individuals (% of the cohort).
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(data not shown). The CKM assay did not detect the
human creatine kinase B-type (CKB) protein (data
not shown). Taken together this data confirms that
these assays can be used to accurately and specif-
ically measure human proteins sTnI, Myl3, FABP3
and CKM. All serum samples were diluted into the
linear detection range of each assay for subsequent
analysis.
Circulating biomarker levels in muscular
dystrophy
To begin to assess the utility of the muscle injury
panel for monitoring disease progression in muscu-
lar dystrophy serum samples from 74 DMD, 38 BMD
and 49 LGMD2B patients and 32 healthy controls
were obtained (Table 1). While the control population
included juveniles as well as younger and older adults
to cover the range of the muscular dystrophy cohorts,
it should be noted that the average age of the DMD
and BMD cohorts is significantly different (P < 0.05)
from the healthy controls while the LGMD2B cohort
was not (data not shown). Standard clinical chem-
istry testing for total serum CK revealed significantly
elevated average total CK levels for all three mus-
cular dystrophy patient groups compared to healthy
controls for this assay (Fig. 1A). The DMD patients
showed the highest mean total serum CK (7443 ± 6357
U/L). This is consistent with the severe muscle damage
and more rapid disease progression observed in DMD
patients [1, 25]. This was followed by the LGMD2B
(4342 ± 3518 U/L) and the BMD (3108 ± 4007 U/L)
patient groups, whereas the healthy volunteers group
had an average serum CK activity of 109 ± 57.61 U/L.
Compared to the healthy control group the mean total
serum CK activity was elevated 28 fold over controls
in BMD patients, 40 fold in LGMD2B patients and
68 fold in DMD patients. Also, as has previously been
Fig. 1. Scatter plots of the serum clinical chemistry and protein serum concentrations in muscular dystrophy patients. (A) Total serum CK,
AST and ALT levels and (B) serum concentrations of sTnI, Myl3, FABP3 and CKM for the DMD, BMD, LGMD2B patient groups and healthy
controls are shown. The line and error bars represent the mean and standard deviation of each group. ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001.
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reported, average serum AST and ALT levels were also
elevated above the healthy volunteer controls for these
analytes in all three patient populations [26, 27].
The serum concentrations of sTnI, Myl3, CKM and
FABP3 were determined in the muscular dystrophy
patients’ samples and healthy controls. While measur-
able amounts of FABP3 and CKM were detected in the
serum of all the healthy controls, the serum concentra-
tions were below the lower limit of quantitation for all
of the subjects for sTnI and 22 of the subjects for Myl3.
In these cases, the concentration for the lower limit of
quantitation of the assays was reported for the samples.
The mean serum concentrations of all four proteins
were significantly elevated in the muscular dystrophy
patient cohorts when compared to controls (Fig. 1B).
Consistent with the total serum CK levels, the serum
concentrations of all four markers were most elevated
in the DMD patient group, followed by LGMD2B and
BMD. Because the sTnI and Myl3 levels in many of
the controls were below the limit of quantitation of
the assay we could not accurately calculate the fold
change over controls for those markers. For CKM the
fold-change in mean serum levels over controls were
17-fold for BMD, 88-fold for DMD and 37-fold for
LGMD2B. Similarly FABP3 levels were ninefold over
mean controls levels in BMD, 13-fold in DMD and 12-
fold in LGMD2B. Comparisons among the different
types of muscular dystrophy (Table S2) revealed sig-
nificantly elevated mean serum concentrations of sTnI
(P < 0.0001) and CKM (P < 0.01) in DMD patients
relative to the levels measured in BMD patients, but
when comparing the levels between the DMD and
LGMD2B cohorts only sTnI showed a statistically
significant (P < 0.05) difference. With the LGMD2B
patients, however, both sTnI and FABP3 levels were
significantly elevated (P < 0.05) over that measured in
BMD patients.
As noted previously the amino acid sequences of
sTnI, Myl3, FABP3 and CKM are highly conserved
between rodent, canine and human. This suggested
these biomarker assays may also be directly applica-
ble to the most commonly used preclinical models of
muscular dystrophy, the mdx mouse and the golden
retriever muscular dystrophy (GRMD) canine model
[28]. In the mdx model all four biomarker concentra-
tions were significantly elevated (P < 0.001) in serum
from adult mdx mice (N = 10) when compared to age-
matched wild-type controls (N = 9, Figure S2). sTnI
had the greatest fold increase in the mean serum
concentration in the mdx mouse when compared wild-
type controls (124 fold), followed by Myl3 (9.7-fold),
CKM (8.8-fold) and FABP3 (3-fold,). All marker
serum levels were significantly increased (P < 0.0001)
in GRMD affected dogs (Supplementary Figure S3),
but a comparison of the mean biomarker serum con-
centrations in GRMD canines (N = 5) to unaffected
controls (N = 7) revealed that CKM had the greatest
fold increase (1,331-fold), followed by sTnI (727-
fold), Myl3 (98.7-fold) and FABP3 (3.1-fold).
Effect of disease progression and treatment in
DMD patients
In DMD patients loss of ambulation typically occurs
between 7 and 12 years old [1]. The effect of ambula-
tory status of the DMD patients on the biomarker levels
was investigated. Twenty-nine of the DMD patients
(39%) in this study were non-ambulant. The non-
ambulant DMD patients had significantly lower levels
of total serum CK activity and sTnI, Myl3, FABP3 and
CKM concentrations when compared to the 46 ambu-
lant DMD patients (Fig. 2A). BMD and LGMD2B
patients can remain ambulant into late adulthood [1,
5] so the number of non-ambulant BMD (N = 9) and
LGMD2B (N = 16) patients was small, but like the
DMD patients, the non-ambulant patients had signif-
icantly lower biomarker levels and total serum CK
activity when compared to the ambulant patients (data
not shown).
As DMD patients get older the majority eventu-
ally develops cardiomyopathy [29]. Twenty-eight of
the DMD patients (38%) were classified as having car-
diac symptoms based on a reduction in ejection fraction
(<55%) or ongoing treatment for cardiomyopathy. The
mean serum levels of all four muscle protein biomark-
ers and total serum CK levels were significantly lower
in the patients with cardiac symptoms when com-
pared to those without (Fig. 2B). It should be noted
that 82% (N = 23) of the patients with cardiac symp-
toms were also non-ambulant. Also, for those patients
with cardiac symptoms where respiratory function was
measured at the time of blood draw (N = 26) the mean
FVC was 46.9 ± 25.4% compared to 84.2 ± 23.0% for
the DMD patients with no noted cardiac symptoms
(N = 35).
Corticosteroids are the most commonly prescribed
drugs for the treatment of DMD and BMD [30]. Sixty-
two of the DMD patients (83%) in the sample set were
being treated with either deflazacort or prednisolone.
There was no significant difference in the mean serum
levels of the muscle protein biomarkers or serum CK
activity between the patients being treated with steroids
and those not taking steroids at the time of evalua-
tion (Figure S4). This data suggests steroid treatment
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Fig. 2. Scatter plots of the protein serum concentrations in DMD patients based on clinical status. Serum concentrations of sTnI, Myl3, FABP3,
CKM and total CK in (A) ambulant (N = 46) and non-ambulant (N = 29) DMD patients or (B) those classified as with (N = 25) and without
(N = 50) cardiomyopathy are shown. The line and error bars represent the mean and standard deviation of each group. ∗∗∗∗P < 0.0001.
does not have a strong effect on the circulating lev-
els of the investigated muscle proteins, but it should
be noted that the number of DMD patients in this
study not actively being treated with steroids was small
(N = 11).
A subset of the DMD patients (N = 26) in this study
had a follow-up evaluation an average of 11.2 ± 3.3
months after the initial examination and serum sam-
ples were taken again. Of these patients 20 had FVC
measurements and 24 had NSAA scores measured
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Fig. 3. No significant change in patient’s serum biomarker concentrations taken approximately one year apart. Serum biomarker concentrations
in serial blood samples from DMD patients (N = 26). Patients were grouped by age and individual serum biomarker concentrations from the
initial (circles) and follow-up samples (squares) were plotted. P values (P) were calculated by two-way ANOVA. For age groups where no P
values is given then P > 0.99 for that comparison.
at the time of the follow-up. We analyzed these
repeated measures both as a single group (data not
shown) and after separating the samples into three age
groups (Fig. 3). While the age groups show a trend
of decreasing circulating levels of all the biomarkers
there were no significant changes in the biomarker lev-
els or total serum CK (data not shown) between the
times of the serial blood collection in either the single
cohort or age group analysis. Additionally, correlation
analysis of the paired differences in serum muscle pro-
tein biomarker levels and FVC and North Star score
between the two timepoints indicated no statistically
significant associations (data not shown).
Correlation of serum biomarkers with clinical
evaluations
Numerous clinical tests are used to evaluate dis-
ease progression in muscular dystrophy patients [12].
FVC is a clinical measure of respiratory function that
has been shown to be a prognostic indicator in DMD
[31]. The NSAA is a clinical scale designed to mea-
sure the functional ability of ambulant DMD patients
[32]. These two clinical assessments were conducted
at the time of blood collection for the majority of the
patients comprising the DMD sample set. To assess
the utility of sTnI, Myl3, CKM or FABP3 as serum
biomarkers of disease progression in DMD patients the
correlation of the serum concentrations of these mark-
ers and the total CK activity to FVC and the NSAA
score was determined. The serum concentrations of all
four muscle protein biomarkers and the total serum CK
activity showed statistically significant (p < 0.0001)
and biologically relevant (r > 0.6) positive correlation
with FVC (Fig. 4A). There was no significant cor-
relation with the NSAA score when only ambulant
patients (N = 32) were analyzed (Fig. 4B). If, however,
the non-ambulant patients, whose NSAA score would
248 P.M. Burch et al. / Serum Biomarkers of Muscular Dystrophy
be classified as zero, were included in the analysis
(N = 61) there was a strong and statistically signifi-
cant positive correlation (r > 0.6, p < 0.0001) between
the NSAA score and the serum concentrations of the
biomarkers (Figure S5).
FVC was also measured for the BMD patients at the
time of blood sampling. Analysis of this data, however,
revealed no statistically significant correlation between
FVC and sTnI, CKM or total serum CK activity
(Figure S6). There was a weak correlation between
FVC and Myl3 (r = –0.35, p = 0.04) and FABP3
(r = –0.36, p = 0.033), but, interestingly, this correla-
tion was negative, in contrast to the strong positive
correlation observed in the DMD patients.
For a majority of the LGMD2B patients numerous
clinical evaluations were conducted at the time of blood
sampling evaluation, including FVC (N = 47) and the
time required to walk ten meters (N = 31). Like for the
BMD patients, none of the serum concentrations of the
biomarkers or the serum CK activity correlated with
the FVC in the LGMD2B patients (Fig. 5A). Simi-
larly, sTnI, FABP3 and CKM serum concentrations
and serum CK activity did not correlate with the time
to walk 10 m in these patients (Fig. 5B). The corre-
lation Myl3 with the time to walk 10 m was stronger
(r = 0.36, p = 0.045) than those determined for the other
markers, but was still a weak association.
Effect of age on biomarker levels
Previous reports have noted a consistent decline
in serum CK activity with age in dystrophinopathy
patients [25, 33, 34]. Serum CK levels peak in early
childhood for both DMD and BMD patients and then
decline at a rate of approximately 18% per year in
DMD patients and 6% per year in BMD patients [25].
Analysis of CK activity versus age for the DMD, BMD
and LGMD2B patient populations assayed here closely
match these previously reported observations (Fig. 6
A, B and C). It should be noted that age or birth-
date information was not available for thirteen DMD
patients, leaving sixty-one subjects for this analysis.
All four muscle protein biomarkers also followed a
similar trend of steady decline that significantly cor-
related with age (data not shown) in DMD, BMD
and LGMD2B patients. Two possible exceptions to
this trend were Myl3 and FABP3 in BMD patients
over sixty years of age, where serum concentrations
of these proteins remained elevated, but the number
of patients in this age range was very small (N = 4).
Finally, the approximate annual rates of decline for
each biomarker were calculated (Table S3). The annual
rate of decrease in total serum CK activity of approx-
imately 18.2 ± 1.4% per year in the DMD patients
closely matched that reported previously [25]. All the
biomarkers and CK showed the most rapid rate of
decline in DMD patients followed by LGMD2B and
BMD patients. Serum CK activity and CKM had the
most rapid rate of decline in all three patient pop-
ulations. FABP3 showed the slowest annual rate of
decline in DMD and BMD patients, at 10.2 ± 1.2%
and 0.1 ± 0.5%, respectively. In LGMD2B patients,
however, Myl3 levels declined at the slowest rate at
approximately 2.0 ± 0.5% per year.
DISCUSSION
To aid the development of the next generation of
therapies for muscular dystrophy new clinical tools are
needed to monitor disease progression and the response
to treatment. Recent reports have used proteomics
approaches to identify serum biomarkers of muscu-
lar dystrophy [14, 23]. Interestingly, but, perhaps not
surprisingly, most of the proteins identified by these
previous studies as significantly different between
healthy control and muscular dystrophy patient cohorts
were of muscle origin. Here we have investigated the
serum concentrations of four proteins that are abun-
dantly expressed in skeletal muscle in DMD, BMD and
LGMD2B patients as potential biomarkers of muscular
dystrophy.
Serum concentrations of sTnI, Myl3, FABP3 and
CKM were all significantly elevated in DMD, BMD
and LGMD2B patients when compared to serum from
healthy controls. The fold increase in average serum
concentrations for all markers when comparing the
muscular dystrophy patients to the healthy controls
suggests they would provide a good dynamic range for
non-invasively measuring the outcome of a therapeutic
intervention. The fact that significantly elevated serum
concentrations were also observed in the mdx mouse
and GRMD canine suggest these biomarkers could be
used as translational biomarkers for drug development.
We did not have ready access to an animal model of
dysferlinopathy for this study, but future testing of
these biomarkers in the SJL or A/J mouse could extend
these observations to a relevant preclinical model of
LGMD2B [35].
Total serum CK activity was also significantly
elevated in all three muscular dystrophy patient popula-
tions, but there are a number of potential advantages the
markers presented here afford. First, based on the pat-
tern of tissue expression, CKM and sTnI, in particular,
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Fig. 4. Correlations of protein serum concentration and clinical measures in DMD patients. A graph of (A) FVC measurement and (B) NSAA
score versus the serum concentrations of sTnI, Myl3, FABP3, CKM and total serum CK for each DMD patient. The Spearman’s rank-order
correlation coefficient (r), P value (P) and number of patients in the sample set (N) is shown for each analysis.
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Fig. 5. Correlations of protein serum concentrations and clinical measures in LGMD2B patients. A graph of the (A) FVC measurement and
(B) the time to walk 10 m test versus serum concentrations of sTnI, Myl3, FABP3, CKM and total serum CK for each LGMD2B patients is
shown. The Spearman’s correlation coefficient (r), P value (P) and number of patients in the sample set (N) is shown for each analysis.
are potentially more specific markers of skeletal mus-
cle injury than total serum CK. This is because
cytosolic CK is a dimer composed of either the cre-
atine kinase, muscle type (CKM) or creatine kinase,
brain type (CKB). The total serum CK assay measures
the enzymatic activity of all CK isoenzymes including
the CK-MM homodimer, predominately expressed in
skeletal muscle, the CK-MB homodimer, principally
released from cardiomyocytes, and CK-BB, expressed
in the brain and at lower levels in numerous other
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Fig. 6. Scatter plots of protein serum concentrations and age in DMD, BMD and LGMD2B patients. A graph of the serum concentrations
of sTnI, Myl3, FABP3, CKM and total serum CK are shown versus the age of the patient for the (A) DMD (N = 61), (B) BMD (N = 38) and
(C) LGMD2B (N = 49) samples.
tissues [13, 36]. Therefore, as has been noted by other
researchers and clinicians, total serum CK cannot be
used to independently distinguish between skeletal
muscle and cardiac damage or can be elevated due
to medical conditions not directly related to muscle
disease [37]. Additionally, whereas serum CK activ-
ity can be affected by low serum glutathione levels
and interactions with certain classes of drugs [15, 38],
these factors would, most likely, have less of an impact
on an ELISA-based assay.
The clinical information available for the DMD
patients allowed further analysis of the effect of dis-
ease progression and treatment on the biomarker levels.
Ambulant patients had significantly higher serum
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concentrations of all four biomarkers and total serum
CK activity than non-ambulant patients. This is con-
sistent with the long-standing observation that serum
CK level increase with physical activity in ambulant
DMD patients [39]. This could be due to an increase
in the rate of release due to contraction or the presence
of relatively more muscle mass in ambulant versus
non-ambulant patients [25]. DMD patients without
cardiomyopathy also had significantly higher serum
concentrations of all four biomarkers and serum CK.
But since the majority of patients with cardiomyopathy
were also non-ambulant it wasn’t possible to deter-
mine if cardiomyopathy alone was a factor in the serum
biomarker levels observed. Finally, there was no signif-
icant difference in the serum biomarkers or CK activity
of DMD patients on or off corticosteroid therapy,
which is perhaps surprising given the improvement
in muscle pathology and rate of disease progression
observed with treatment [30]. A limiting factor in
this analysis, however, is the fact that the number of
DMD patients not being treated with corticosteroids
was small (N = 11). Also, the multiple mechanisms of
action proposed for corticosteroid therapy [40] could
conceivably be expected to both increase (i.e. increased
muscle mass) and decrease (i.e. reduced inflammation)
the release of muscle-derived proteins into circulation.
Ultimately, the utility of these biomarkers for monitor-
ing the response to a therapy will have to be determined
on a case-by-case basis.
While it was a bit surprising there was no significant
change detected in the biomarker levels in the subset
of DMD patients where serial samples were collected,
there are a number of possible reasons for this. First,
although the average time between blood samples was
approximately a year the range was wide (3.9–18.4
months). Also, although our data indicates the aver-
age serum concentrations of the biomarkers decrease
approximately 10–19% per year there is probably a
wide range in this rate of decline in individual patients
and, as our data suggests, at different stages of the
disease. A follow-up longitudinal study where blood
samples are consistently collected a year or more apart
will be needed to address this aspect of the study more
thoroughly.
FVC is a clinical measure that provides a quantita-
tive assessment of weakness in the respiratory muscles
and is a prognostic biomarker in DMD patients [31].
We showed that sTnI, Myl3, FABP3 and CKM have
a significant positive correlation with FVC in the
DMD patient population, supporting their utility as
a non-invasive biomarker for monitoring respiratory
muscle weakness. Interestingly, this correlation with
FVC did not extend to the BMD, indicating the serum
biomarkers may not have utility in monitoring pro-
gressive muscle weakness in this patient population.
It should be noted, though, that disease progression
and the involvement of the respiratory muscles is much
slower and more variable in BMD than DMD [41]. The
same lack of correlation between the biomarker lev-
els and FVC was also seen in the LGMD2B patients,
but this result fits with the clinical observation that
LGMD2B does not typically affect the respiratory
muscles [4].
Correlation analysis of other functional clinical end-
points also gave mixed results. The NSAA score is a
clinical test that measures the ability of DMD patients
to independently perform a series of mobility tests [32].
In the DMD patients, there was no significant corre-
lation of the biomarker levels or total serum CK with
the NSAA score, but this only allowed the analysis of a
minority (N = 32) of the DMD patients in the study. It’s
worth noting that a similar lack of correlation between
this NSAA and other proposed muscular dystrophy
serum biomarkers has been reported including multi-
ple miRNA [18], MMP-9 and TIMP-1 [21], which may
indicate that this clinical assessment has limited utility
when evaluating the value of serum biomarkers. Simi-
larly, sTnI, CKM and FABP3 did not correlate with the
clinical test of the time to walk 10 m in the LGMD2B
patients. The correlation of Myl3 with the 10 m walk
test, though weak, suggests it might have utility as
a non-invasive biomarker of muscle performance in
LGMD2B patients. Future studies with a larger sam-
ple size and, ideally, longitudinal data would be needed
to confirm this observation.
A person’s muscle mass is one significant factor
influencing total serum CK levels [36], in that the total
mass would impact the amount of creatine kinase pro-
tein available for release into circulation upon muscle
injury. Although we have not specifically analyzed the
effect of muscle mass on sTnI, CKM, FABP3 and Myl3
serum concentrations here it would be expected to have
a similar impact. It is indirectly reflected in the obser-
vation that the serum concentrations of the biomarkers
decrease with age within the three muscular dystro-
phy populations, since muscle mass decreases with
disease progression [1]. Age is also a potential con-
founding factor for these biomarkers. We evaluated
age as a covariate and found it collinear with the clini-
cal endpoints. The clinical endpoints are more relevant
to disease status and biomarker changes so age was
excluded from the models to avoid confounding. These
observations have implications for the interpretation of
changes in the serum concentrations of the biomarkers
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in monitoring disease progression or the response to
therapeutic intervention since a reduction in the levels
in a particular patient could reflect improved muscle
integrity and the slowing of disease progression or,
conversely, the continued loss of muscle mass due
to disease progression or aging. Also, recent physi-
cal activity can rapidly and dramatically increase total
serum CK activity [36]. The observation that ambulant
patients have significantly higher serum concentrations
of all four biomarkers suggests that physical activity is
a factor for them as well, although further work will be
needed to understand the magnitude and timing of the
release of the proteins into circulation after exercise.
There were some notable differences in the charac-
teristics of the serum biomarker in the different forms
of muscular dystrophy. First, in DMD patients CKM
showed the greatest fold increase in serum concentra-
tion relative to the healthy controls, whereas in BMD
and LGMD2B it was Myl3. The strong correlation
between the four biomarkers and FVC in DMD, but
the lack of correlation in BMD, while puzzling, suggest
disease-dependent differences in the release or elimi-
nation of the biomarker proteins in circulation despite
a decline in muscle function. Also, the analysis of the
annual rate of decline of the biomarkers serum con-
centrations with age showed that while CKM declined
the most rapidly and FABP3 the least rapidly in DMD
and BMD, in the LGMD2B patient population FABP3
declined at a rate slightly greater than CKM. A follow-
up longitudinal study would be needed to investigate
this observation further.
The different biomarker profiles in the three
muscular dystrophies studied here suggest different
mechanisms regulating the release of the proteins
into circulation. As has been suggested by other
researchers, the release of myofibrillar proteins, such
as myosin light chain and the troponins, likely involves
proteolytic cleavage during inflammation and necro-
sis, whereas cytoplasmic proteins, such as FABP3
and CK, could be more directly released into cir-
culation through a rupture in the sarcolemma [23].
Also, the common assumption is that muscle-derived
proteins are released into circulation from membrane
tears caused by mechanical injury during muscle con-
traction. It follows, then, that the contents of muscle
tissue with diminished integrity due to a lack of dys-
trophin or dysferlin expression would passively leak
into circulation in greater amounts than healthy mus-
cle. This “leaky” muscle argument has, however, been
challenged by a number of researchers [13, 42]. In
fact, studies comparing the repair of mdx and con-
trol wild-type muscle fibers showed no difference in
their ability to reseal sarcolemma damage, whereas
membrane resealing in muscle fibers from dysferlin
deficient mice was delayed [43]. Recently it has been
shown that myosin light chain 1 and 3 (MLC1-3), is
exported from skeletal muscle via LAMP-1 positive
vesicles in dystrophic muscle [44]. Taken together, this
indicates the rate and mechanism by which muscle-
derived proteins are released into circulation may be
both biomarker and disease dependent.
Here we investigated the utility of measuring serum
concentrations of sTnI, Myl3, FABP3 and CKM
in DMD, BMD and LGMD2B patients. While this
analysis revealed that these serum biomarkers still
display some of the potential disadvantages of total
serum CK activity, the potentially increased specificity
for skeletal muscle injury and the correlation with
clinical end-points in DMD and LGMD2B patients
suggested that these biomarkers could be a valuable
non-invasive tool for monitoring disease progression
and therapeutic response, particularly when cardiomy-
opathy is present. Future work will be directed at
determining if one or a panel of these biomarkers is
particularly valuable for monitoring clinical outcomes
in a subset of patients or for a particular therapeutic
intervention.
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